Eledon Pharmaceuticals, Inc. financial data

Symbol
ELDN on Nasdaq
Industry
Pharmaceutical Preparations
Location
19800 Macarthur Blvd., Suite 250, Irvine, CA
State of incorporation
DE
Fiscal year end
December 31
Former names
Novus Therapeutics, Inc. (to 12/22/2020), Tokai Pharmaceuticals Inc (to 5/4/2017)
Latest financial report
10-Q - Q2 2024 - Aug 19, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.49K % +38.1%
Debt-to-equity 1.87K % +7253%
Return On Equity -2.22K % -1211%
Return On Assets -112 % +16.6%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 39.7M shares +68.4%
Common Stock, Shares, Outstanding 38.5M shares +67.1%
Entity Public Float 25.6M USD -23.6%
Common Stock, Value, Issued 39K USD +69.6%
Weighted Average Number of Shares Outstanding, Basic 42.3M shares +76.1%
Weighted Average Number of Shares Outstanding, Diluted 42.3M shares +76.1%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 32.5M USD +8.32%
General and Administrative Expense 14.4M USD +19.1%
Operating Income (Loss) -46.9M USD +48.3%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -88M USD -139%
Net Income (Loss) Attributable to Parent -109M USD +25.3%
Earnings Per Share, Basic -3.09 USD/shares +62.8%
Earnings Per Share, Diluted -3.09 USD/shares +62.8%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 26M USD -36.4%
Cash, Cash Equivalents, and Short-term Investments 83.6M USD +17.1%
Other Assets, Current 157K USD -34%
Assets, Current 87.2M USD +18.5%
Operating Lease, Right-of-Use Asset 621K USD +12.3%
Goodwill 0 USD
Other Assets, Noncurrent 255K USD +13.8%
Assets 120M USD +12.8%
Accounts Payable, Current 2.15M USD -2.23%
Liabilities, Current 6.03M USD +23%
Deferred Income Tax Liabilities, Net 1.75M USD 0%
Operating Lease, Liability, Noncurrent 386K USD +110%
Liabilities 129M USD +105%
Retained Earnings (Accumulated Deficit) -388M USD -38.8%
Stockholders' Equity Attributable to Parent -8.5M USD -119%
Liabilities and Equity 120M USD +12.8%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -8.74M USD +11.9%
Net Cash Provided by (Used in) Investing Activities 9.78M USD
Common Stock, Shares Authorized 200M shares 0%
Common Stock, Shares, Issued 38.5M shares +67.1%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 1.04M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 26M USD -36.4%
Deferred Tax Assets, Valuation Allowance 30.8M USD +42.2%
Deferred Tax Assets, Gross 36.8M USD +32.1%
Operating Lease, Liability 655K USD +14.1%
Lessee, Operating Lease, Liability, to be Paid 673K USD +15%
Operating Lease, Liability, Current 269K USD -31%
Lessee, Operating Lease, Liability, to be Paid, Year Two 197K USD
Lessee, Operating Lease, Liability, to be Paid, Year One 191K USD -50.8%
Operating Lease, Weighted Average Discount Rate, Percent 0.02 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 18K USD +63.6%
Lessee, Operating Lease, Liability, to be Paid, Year Three 100K USD
Deferred Tax Assets, Operating Loss Carryforwards 18.1M USD +18.8%
Preferred Stock, Shares Authorized 5M shares 0%
Unrecognized Tax Benefits 3.64M USD +36.5%
Operating Lease, Payments 102K USD +22.9%
Share-based Payment Arrangement, Expense 8.2M USD +21.3%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%